Immunotherapy and bevacizumab for advanced ovarian clear cell cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of an immunotherapy drug (QL1706) and a targeted therapy (bevacizumab) for women with newly diagnosed advanced ovarian clear cell carcinoma. The goal is to see if this combination works better than standard treatment after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 and under 75 years old.
- You must have been diagnosed with ovarian clear cell carcinoma that has not spread too far (stage IC to IV).
- You must be scheduled for surgery to remove the tumor (primary debulking surgery).
- You cannot have received any chemotherapy, immunotherapy, or targeted therapy for this cancer before.
- Your kidney, liver, and blood cell counts must meet certain minimum levels.
- You cannot have an active autoimmune disease, uncontrolled infection, or serious heart condition.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests a treatment made of an investigational gene-based drug plus standard “platinum” chemotherapy and bevacizumab, compared with standard chemotherapy and bevacizumab. It’s for ovarian/fallopian tube/primary peritoneal cancers that have not responded to platinum chemotherapy or came back quickly.
This trial tests a combination of three drugs (RC48, AK104, and bevacizumab) for ovarian clear cell carcinoma, a type of ovarian cancer. The goal is to see if this combination can help shrink or control the cancer in people who have not had many prior treatments.
This trial tests a new combination of drugs—QL1706 (which targets two immune checkpoints), nab-paclitaxel, and bevacizumab—for people with ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a new immunotherapy drug (QL1706) for people with advanced endometrial cancer whose previous immunotherapy stopped working. It aims to see if this different approach can help when standard treatments have failed.
This trial studies whether adding pembrolizumab to bevacizumab (and sometimes an anti-CD40 drug) can help control recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also looks at whether the treatment can shrink tumors and keep them from growing for longer.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tovorilimab) plus bevacizumab and chemotherapy before surgery for advanced ovarian cancer that cannot be removed surgically at first. The goal is to see if this treatment can shrink the tumor enough to allow surgery.
Hear when a new Ovarian Clear Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.